770
Participants
Start Date
April 9, 2025
Primary Completion Date
April 27, 2029
Study Completion Date
October 15, 2032
Sacituzumab tirumotecan
IV Infusion
Bevacizumab
IV Infusion
H1 receptor antagonist
Rescue medication taken per approved product label before sacituzumab tirumotecan
H2 receptor antagonist
Rescue medication taken per approved product label before sacituzumab tirumotecan
Acetaminophen (or equivalent)
Rescue medication taken per approved product label before sacituzumab tirumotecan
Dexamethasone (or equivalent)
Rescue medication taken per approved product label before sacituzumab tirumotecan
Steroid mouthwash (dexamethasone or equivalent)
Rescue medication taken orally 4 times daily
RECRUITING
Mackay Memorial Hospital ( Site 2604), Taipei
RECRUITING
National Cheng Kung University Hospital ( Site 2602), Tainan City
RECRUITING
Blacktown Hospital ( Site 0211), Sydney
RECRUITING
Epworth Freemasons ( Site 0217), East Melbourne
RECRUITING
Frankston Hospital ( Site 0216), Frankston
RECRUITING
Gallipoli Medical Research Ltd ( Site 0214), Brisbane
RECRUITING
National Cancer Center ( Site 2305), Goyang-si
RECRUITING
Hospital Universitario Reina Sofia ( Site 2406), Córdoba
RECRUITING
Institut Català d'Oncologia (ICO) - Girona ( Site 2402), Girona
RECRUITING
Clinica Universidad de Navarra ( Site 2407), Madrid
RECRUITING
Hospital Ramon y Cajal ( Site 2405), Madrid
RECRUITING
Sarasota Memorial Hospital ( Site 0075), Sarasota
ACTIVE_NOT_RECRUITING
St. Dominic's Hospital ( Site 0064), Jackson
RECRUITING
Taichung Veterans General Hospital ( Site 2603), Taichung
RECRUITING
University of Cincinnati Medical Center ( Site 0090), Cincinnati
RECRUITING
Nebraska Methodist Hospital ( Site 0053), Omaha
RECRUITING
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa
RECRUITING
Rutgers Cancer Institute of New Jersey ( Site 0071), New Brunswick
RECRUITING
Women & Infants Hospital ( Site 0050), Providence
RECRUITING
Kurume University Hospital ( Site 1640), Kurume
RECRUITING
Saitama Medical University International Medical Center ( Site 1632), Hidaka
RECRUITING
Cancer Institute Hospital of JFCR ( Site 1639), Koto
RECRUITING
Keio University Hospital ( Site 1636), Shinjyuku
RECRUITING
Niigata Cancer Center Hospital ( Site 1633), Niigata
RECRUITING
Severance Hospital ( Site 2302), Seodaemun-Gu
RECRUITING
Asan Medical Center ( Site 2304), Songpa-gu
RECRUITING
Seoul National University Hospital ( Site 2301), Seoul
RECRUITING
Samsung Medical Center ( Site 2303), Seoul
RECRUITING
Hospital Vall D Hebron ( Site 2403), Barcelona
RECRUITING
ICO L Hospitalet ( Site 2408), Barcelona
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
GOG Foundation
NETWORK
Merck Sharp & Dohme LLC
INDUSTRY